Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG); Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [YC20210105]; 2022CSCO key program [Y-2021AST/zd-0119]
第一作者机构：[1]Sichuan Canc Hosp, Dept Med Oncol, Sichuan Clin Res Ctr Canc, Chengdu, Peoples R China[2]Univ Elect Sci & Technol China, Sichuan Canc Ctr, Inst, Affiliated Canc Hosp, Chengdu, Peoples R China
推荐引用方式(GB/T 7714)：
Jin Z..Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study[J].ANNALS OF ONCOLOGY.2024,35:S851-S852.doi:10.1016/j.annonc.2024.08.1402.
APA：
Jin, Z..(2024).Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study.ANNALS OF ONCOLOGY,35,
MLA：
Jin, Z.."Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study".ANNALS OF ONCOLOGY 35.(2024):S851-S852
医学